Ribobio (苏州瑞博生物技术)

IPO

Advancing RNAi therapy for a new era of human health

Public · Guangzhou, China · Founded 2004

Headquarters
Guangzhou
Employees
201–500
Founded
2004
Business Model
B2B
Last Round
Series CApr 2020
Rounds
4
Type
Public

About

RiboBio (Suzhou Ribo Life Science Co., Ltd., HKEX: 06938.HK) is a clinical-stage biotechnology company focused on RNA interference (RNAi) technology and the development and commercialization of small nucleic acid drugs, founded in 2004 and headquartered in Guangzhou, China. The company has established a fully integrated small nucleic acid drug development platform covering the entire lifecycle from early research to commercialization, with therapeutic programs targeting cardiovascular, metabolic, renal, liver, and central nervous system diseases. RiboBio is Asia's largest oligonucleotide-based drug manufacturer and operates China's first cGMP-certified oligonucleotide API facility. The company maintains international R&D centers and has partnered with global pharmaceutical companies including Madrigal Pharmaceuticals on joint development programs.

Summary

Ribobio (苏州瑞博生物技术) is a Biotech company based in Guangzhou, China, founded in 2004. Its most recent funding was a Series C round in Apr 2020. Investors include Hong Kong Stock Exchange and Hengxu Capital.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Series CSeries CApr 2020

Sign up to see all 5 events

Funding: Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ribobio (苏州瑞博生物技术) on Indexed.vc
<a href="https://indexed.vc/companies/ribobio"><img src="https://indexed.vc/api/badge/company/ribobio" alt="Ribobio (苏州瑞博生物技术) on Indexed.vc" width="260" height="76" /></a>